This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lusis, E. A. Articles by Perry, A. Search for Related Content PubMed PubMed Citation Articles by Lusis, E. A. Articles by Perry, A.

Integrative Genomic Analysis Identifies NDRG2 as a Candidate Tumor Suppressor Gene Frequently Inactivated in Clinically Aggressive Meningioma

¹ Division of Neuropathology, Departments of ² Pathology and Immunology, ³ Neurosurgery, and ⁴ Neurology, Washington University School of Medicine, St. Louis, Missouri; and ⁵ Department of Neuropathology, Heinrich-Heine-University, Düsseldorf, Germany

Requests for reprints: Arie Perry, Division of Neuropathology, Washington University School of Medicine, Campus Box 8118, 660 South Euclid Avenue, St. Louis, MO 63110. Phone: 314-362-9130; Fax: 314-362-4096; E-mail: aperry{at}wustl.edu.

Although meningiomas are common central nervous system tumors, little is known about the genetic events responsible for malignant progression. In this study, we employed gene expression profiling to identify transcripts whose expression was lost in anaplastic (WHO grade III) versus benign (WHO grade I) meningioma. Approximately 40% of genes down-regulated in anaplastic meningioma were localized to chromosomes 1p and 14q. One specific gene located at 14q11.2, NDRG2, was consistently down-regulated in grade III meningioma, a finding which we validated at both the transcript and protein levels in independent sets of clinically and pathologically diverse meningiomas. Loss of NDRG2 expression was also seen in a subset of lower-grade meningiomas, including atypical meningiomas (WHO grade II) with clinically aggressive behavior. Furthermore, we found that the loss of NDRG2 expression was significantly associated with hypermethylation of the NDRG2 promoter. Collectively, these data identify NDRG2 as the first specific candidate tumor suppressor gene on chromosome 14q that is inactivated during meningioma progression. In addition, these findings highlight the utility of combining genomic, epigenetic, and expression data to identify clinically significant tumor biomarkers, and suggest that NDRG2 expression will be a useful and functionally relevant biomarker to predict aggressive behavior in patients with meningioma.

This article has been cited by other articles:

				P. Jun, C. Hong, A. Lal, J. M. Wong, M. W. McDermott, A. W. Bollen, C. Plass, W. A. Held, D. J. Smiraglia, and J. F. Costello Epigenetic silencing of the kinase tumor suppressor WNK2 is tumor-type and tumor-grade specific Neuro Oncology, August 1, 2009; 11(4): 414 - 422. [Abstract] [Full Text] [PDF]

				V. Melotte, M. H. F. M. Lentjes, S. M. van den Bosch, D. M. E. I. Hellebrekers, J. P. J. de Hoon, K. A. D. Wouters, K. L. J. Daenen, I. E. J. M. Partouns-Hendriks, F. Stessels, J. Louwagie, et al. N-Myc Downstream-Regulated Gene 4 (NDRG4): A Candidate Tumor Suppressor Gene and Potential Biomarker for Colorectal Cancer J Natl Cancer Inst, July 1, 2009; 101(13): 916 - 927. [Abstract] [Full Text] [PDF]

				A. Kim, M.-J. Kim, Y. Yang, J. W. Kim, Y. I. Yeom, and J.-S. Lim Suppression of NF-{kappa}B activity by NDRG2 expression attenuates the invasive potential of highly malignant tumor cells Carcinogenesis, June 1, 2009; 30(6): 927 - 936. [Abstract] [Full Text] [PDF]

				Y.-J. Kim, S. Y. Yoon, J.-T. Kim, E. Y. Song, H. G. Lee, H. J. Son, S. Y. Kim, D. Cho, I. Choi, J. H. Kim, et al. NDRG2 expression decreases with tumor stages and regulates TCF/{beta}-catenin signaling in human colon carcinoma Carcinogenesis, April 1, 2009; 30(4): 598 - 605. [Abstract] [Full Text] [PDF]

				V. C. Foletta, M. J. Prior, N. Stupka, K. Carey, D. H. Segal, S. Jones, C. Swinton, S. Martin, D. Cameron-Smith, and K. R. Walder NDRG2, a novel regulator of myoblast proliferation, is regulated by anabolic and catabolic factors J. Physiol., April 1, 2009; 587(7): 1619 - 1634. [Abstract] [Full Text] [PDF]

				N. Liu, L. Wang, X. Li, Q. Yang, X. Liu, J. Zhang, J. Zhang, Y. Wu, S. Ji, Y. Zhang, et al. N-Myc downstream-regulated gene 2 is involved in p53-mediated apoptosis Nucleic Acids Res., September 1, 2008; 36(16): 5335 - 5349. [Abstract] [Full Text] [PDF]

				D. C. Lee, Y. K. Kang, W. H. Kim, Y. J. Jang, D. J. Kim, I. Y. Park, B. H. Sohn, H. A. Sohn, H. G. Lee, J. S. Lim, et al. Functional and Clinical Evidence for NDRG2 as a Candidate Suppressor of Liver Cancer Metastasis Cancer Res., June 1, 2008; 68(11): 4210 - 4220. [Abstract] [Full Text] [PDF]

				L. Bethke, E. Webb, A. Murray, M. Schoemaker, M. Feychting, S. Lonn, A. Ahlbom, B. Malmer, R. Henriksson, A. Auvinen, et al. Functional Polymorphisms in Folate Metabolism Genes Influence the Risk of Meningioma and Glioma Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1195 - 1202. [Abstract] [Full Text] [PDF]

				S.-C. Choi, K. D. Kim, J.-T. Kim, J. W. Kim, H. G. Lee, J.-M. Kim, Y.-S. Jang, D.-Y. Yoon, K. I. Kim, Y. Yang, et al. Expression of human NDRG2 by myeloid dendritic cells inhibits down-regulation of activated leukocyte cell adhesion molecule (ALCAM) and contributes to maintenance of T cell stimulatory activity J. Leukoc. Biol., January 1, 2008; 83(1): 89 - 98. [Abstract] [Full Text] [PDF]

				A. Maillo, A. Orfao, A. B. Espinosa, J. M. Sayagues, M. Merino, P. Sousa, M. Lara, and M. D. Tabernero Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone Neuro Oncology, October 1, 2007; 9(4): 438 - 446. [Abstract] [Full Text] [PDF]

				L. Shao, Y. Cui, H. Li, Y. Liu, H. Zhao, Y. Wang, Y. Zhang, K. M. Ng, W. Han, D. Ma, et al. CMTM5 Exhibits Tumor Suppressor Activities and Is Frequently Silenced by Methylation in Carcinoma Cell Lines Clin. Cancer Res., October 1, 2007; 13(19): 5756 - 5762. [Abstract] [Full Text] [PDF]

				D. C.-l. Lam, L. Girard, R. Ramirez, W.-s. Chau, W.-s. Suen, S. Sheridan, V. P.C. Tin, L.-p. Chung, M. P. Wong, J. W. Shay, et al. Expression of Nicotinic Acetylcholine Receptor Subunit Genes in Non-Small-Cell Lung Cancer Reveals Differences between Smokers and Nonsmokers Cancer Res., May 15, 2007; 67(10): 4638 - 4647. [Abstract] [Full Text] [PDF]